









Markets
/
Stocks
/
nasdaq-meso
/

Mesoblast Ltd

MESO

16.020USD

+0.160+1.01%

Close 09/29, 16:00（ET）Quotes delayed by 15 min

2.05BMarket Cap

LossP/E TTM



Mesoblast Ltd

16.020

+0.160+1.01%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Mesoblast Ltd

Currency: USD Updated: 2025-09-29

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite strong stock market performance and technicals, the fundamentals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Mesoblast Ltd's Score

Industry at a Glance

Industry Ranking

114 / 505

Overall Ranking

215 / 4714

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

27.000

Target Price

+70.24%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Mesoblast Ltd Highlights

StrengthsRisks

Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 129.28% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 17.20M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 24.73.

Undervalued

The company’s latest PE is -17.25, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 4.04M shares, increasing 11.84% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 1.63K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-29

The company's current financial score is 5.55, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 3.16M, representing a year-over-year decrease of 6.85%, while its net profit experienced a year-over-year decrease of 47.31%.

Score

Industry at a Glance

Previous score

5.55

Change



Financials

5.52

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.59

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.48

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.04

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.13

Key Metrics

Free cash flow

No Data

Mesoblast Ltd's Company Valuation

Currency: USD Updated: 2025-09-29

The company’s current valuation score is 7.41, which is higher than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -17.25, which is -100.00% below the recent high of 0.00 and -28.65% above the recent low of -22.19.

Score

Industry at a Glance

Previous score

7.41

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 114/505

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-29

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Mesoblast Ltd is 27.00, with a high of 30.00 and a low of 24.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

27.000

Target Price

+70.24%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Mesoblast Ltd

MESO

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Exact Sciences Corp

EXAS

argenx SE

ARGX

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-29

The company’s current price momentum score is 9.31, which is higher than the Biotechnology & Medical Research industry's average of 6.76. Sideways: Currently, the stock price is trading between the resistance level at 17.89 and the support level at 13.41, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.28

Change

0.03

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.086

Buy

RSI(14)

54.574

Neutral

STOCH(KDJ)(9,3,3)

51.014

Sell

ATR(14)

0.626

Low Volatility

CCI(14)

25.825

Neutral

Williams %R

45.344

Neutral

TRIX(12,20)

0.379

Sell

StochRSI(14)

29.656

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

16.152

Sell

MA10

16.104

Sell

MA20

15.286

Buy

MA50

15.426

Buy

MA100

13.373

Buy

MA200

13.965

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-29

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.97. The latest institutional shareholding proportion is 3.16%, representing a quarter-over-quarter decrease of 1.12%. The largest institutional shareholder is CI Select Canadian Equity Fund, holding a total of 7.12K shares, representing 0.01% of shares outstanding, with 29.11% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

565.89K

-3.15%

Goldman Sachs & Company, Inc.

257.14K

Morgan Stanley & Co. International Plc

313.52K

+91.76%

Susquehanna International Group, LLP

260.94K

+69.47%

Summit Wealth Strategies

198.16K

+36.05%

Morgan Stanley & Co. LLC

224.26K

-0.44%

UBS Financial Services, Inc.

137.34K

-16.84%

Aperio Group, LLC

132.49K

+3.84%

Risk Assessment

Currency: USD Updated: 2025-09-29

The company’s current risk assessment score is 4.02, which is higher than the Biotechnology & Medical Research industry's average of 3.49. The company's beta value is 2.30. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.